Nav: Home

A comparison between quetiapine and aripiprazole for treatment of schizophrenia

July 13, 2016

Schizophrenia is a common cause of incapacity and is ranked as the third-most-disabling illness subsequent to dementia and quadriplegia. Nearly, 75% of persons with schizophrenia have continuing problems with recurrent psychotic episodes. Antipsychotics are effective in both the acute and chronic (maintenance) treatment of schizophrenia and other psychotic disorders. They differ in their pharmacology, kinetics, overall efficacy/effectiveness and tolerability, but perhaps more importantly, response and tolerability differs between patients. This variability of individual response means that there is no clear first line antipsychotic suitable for all patients. While there is increasing proof that most atypical antipsychotics offer benefits over typical antipsychotics, few long-term trials have openly matched SGAs. Quetiapine is a SGA with small tendency for locomotors side effects. It is prescribed for treatment of schizophrenia and other psychoses. Aripiprazole, a partial agonist of dopamine D2 receptor, is a novel antipsychotic approved for the management of schizophrenia and bipolar I disorder. Since, in comparison with older atypical antipsychotics, like olanzapine and risperidone, aripiprazole and quetiapine are among the newest and safest SGAs, therefore in the present assessment the safety and efficacy of them had been compared with each other in a non-western patient population. In this regard, 50 schizophrenic patients entered into two comparable groups for participation in a 12-week, double-blind study, for random assignment to quetiapine or aripiprazole. Based on the outcomes of the current study, no significant difference was evident between aripiprazole and quetiapine regarding improvement of positive and negative symptoms of schizophrenia. For example, while both of aripiprazole and quetiapine demonstrated some efficacy in alleviation of positive symptoms, their efficacy was not so pronounced with respect to negative symptoms. General psychopathology and insight, too, revealed significant improvement with aripiprazole and quetiapine in comparison to other drugs. Also, in neither groups was there evidence of any significant increase in extrapyramidal adverse effects.
-end-
Reference: Shafti S.S. and Kaviani H., (2016). A Comparison Between Quetiapine and Aripiprazole for Treatment of Schizophrenia: A Double Blind Contrast, Curr Psychopharmacol., DOI:10.2174/

Bentham Science Publishers

Related Schizophrenia Articles:

Dietary supplement may help with schizophrenia
A dietary supplement, sarcosine, may help with schizophrenia as part of a holistic approach complementing antipsychotic medication, according to a UCL researcher.
Schizophrenia: Adolescence is the game-changer
Schizophrenia may be related to the deletion syndrome. However, not everyone who has the syndrome necessarily develops psychotic symptoms.
Study suggests overdiagnosis of schizophrenia
In a small study of patients referred to the Johns Hopkins Early Psychosis Intervention Clinic (EPIC), Johns Hopkins Medicine researchers report that about half the people referred to the clinic with a schizophrenia diagnosis didn't actually have schizophrenia.
The ways of wisdom in schizophrenia
Researchers at UC San Diego School of Medicine report that persons with schizophrenia scored lower on a wisdom assessment than non-psychiatric comparison participants, but that there was considerable variability in levels of wisdom, and those with higher scores displayed fewer psychotic symptoms.
Recognizing the uniqueness of different individuals with schizophrenia
Individuals diagnosed with schizophrenia differ greatly from one another. Researchers from Radboud university medical center, along with colleagues from England and Norway, have demonstrated that very few identical brain differences are shared amongst different patients.
More Schizophrenia News and Schizophrenia Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...